Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLASHPOINT: FG001 Imaging in Transoral Robotic and Neck Dissection Surgery for Head and Neck Cancer
2025-522845-23-00Phase 2Authorised
- Sponsor
- Rigshospitalet
- Start
- Oct 2026
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of FG001 in oropharyngeal squamous cell carcinoma (OPSCC) and Oral Mucosal Carcinoma (2 cohorts), sponsored by Rigshospitalet. Primary endpoints: Sensitivity of FG001 for detection of primary OPSCC during TORS and Node-level sensitivity of FG001 for detection of metastatic lymph nodes. Planned start Oct 2026; status: authorised.
02
Drugs
FG001
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)Oral Mucosal Carcinoma
Beyond the preview
Go deeper on 2025-522845-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522845-23-00.